Edivoxetine

DB09184InvestigationalSmall molecule

Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment.... Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.

Mechanism: Pharmacologically active on Sodium-dependent noradrenaline transporter
Curator reviewed
Formula / weight: C₁₈H₂₆FNO₄ · 339.407 g/mol (avg)
Code names: LY-2216684

Resolves to

Compound

UNII3W9N3F4JOOCAS1194508-25-2ChEMBLCHEMBL2103857PubChem11186829

Structure

InChIKeyCPBHSHYQQLFAPW-ZWKOTPCHSA-NSMILES[H][C@]1(CNCCO1)[C@@](O)(CC1=C(OC)C=CC(F)=C1)C1CCOCC1

Targets

P23975SLC6A2

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

680Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Edivoxetine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account